- Prospective identification of tumorigenic prostate cancer stem cells
Anne T Collins
Yorkshire Cancer Research Unit, Department of Biology, University of York, York, United Kingdom
Cancer Res 65:10946-51. 2005
..The identification of a prostate cancer stem cell provides a powerful tool to investigate the tumorigenic process and to develop therapies targeted to the stem cell...
- Integrative genomic profiling of human prostate cancer
Barry S Taylor
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Cancer Cell 18:11-22. 2010
..The genomic and clinical outcome data from these patients are now made available as a public resource...
- Sipuleucel-T immunotherapy for castration-resistant prostate cancer
Philip W Kantoff
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
N Engl J Med 363:411-22. 2010
..Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer...
- Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
Scott A Tomlins
Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109 0602, USA
Science 310:644-8. 2005
..These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer...
- Abiraterone and increased survival in metastatic prostate cancer
Johann S de Bono
Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom
N Engl J Med 364:1995-2005. 2011
..We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy...
- Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland
Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden
N Engl J Med 343:78-85. 2000
..The contribution of hereditary factors to the causation of sporadic cancer is unclear. Studies of twins make it possible to estimate the overall contribution of inherited genes to the development of malignant diseases...
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
Ian F Tannock
Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
N Engl J Med 351:1502-12. 2004
..We compared such treatment with docetaxel plus prednisone in men with this disease...
- Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome
Vincent C Lombardi
Whittemore Peterson Institute, Reno, NV 89557, USA
Science 326:585-9. 2009
..These findings raise the possibility that XMRV may be a contributing factor in the pathogenesis of CFS...
- The genomic complexity of primary human prostate cancer
Michael F Berger
The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA
Nature 470:214-20. 2011
..Thus, genomic rearrangements may arise from transcriptional or chromatin aberrancies and engage prostate tumorigenic mechanisms...
- Screening and prostate-cancer mortality in a randomized European study
Fritz H Schroder
Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
N Engl J Med 360:1320-8. 2009
..The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate the effect of screening with prostate-specific-antigen (PSA) testing on death rates from prostate cancer...
- PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
Department of Pathology, College of Physicians and Surgeons, Columbia University, 630 West 168 Street, New York, NY 10032, USA
Science 275:1943-7. 1997
..These homologies suggest that PTEN may suppress tumor cell growth by antagonizing protein tyrosine kinases and may regulate tumor cell invasion and metastasis through interactions at focal adhesions...
- Radical prostatectomy versus observation for localized prostate cancer
Timothy J Wilt
Center for Chronic Disease Outcomes Research, Minneapolis Veterans Affairs VA Health Care System, and Section of General Medicine, University of Minnesota School of Medicine, Minneapolis, USA
N Engl J Med 367:203-13. 2012
..The effectiveness of surgery versus observation for men with localized prostate cancer detected by means of prostate-specific antigen (PSA) testing is not known...
- The polycomb group protein EZH2 is involved in progression of prostate cancer
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Nature 419:624-9. 2002
..Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression...
- Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
The Michigan Center for Translational Pathology, Ann Arbor, USA
Nature 457:910-4. 2009
..Here, by profiling the metabolomic alterations of prostate cancer progression, we reveal sarcosine as a potentially important metabolic intermediary of cancer cell invasion and aggressivity...
- Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, 1275 York Avenue, New York, New York 10021, USA
Nature 436:725-30. 2005
..Our results demonstrate the relevance of cellular senescence in restricting tumorigenesis in vivo and support a model for cooperative tumour suppression in which p53 is an essential failsafe protein of Pten-deficient tumours...
- Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
Daniel P Petrylak
Columbia University, Herbert Irving Comprehensive Cancer Center, New York, USA
N Engl J Med 351:1513-20. 2004
..We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone-independent prostate cancer...
- Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant
Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, United States of America
PLoS Pathog 2:e25. 2006
..These findings also raise questions about the possible relationship between exogenous infection and cancer development in genetically susceptible individuals...
- International variation in prostate cancer incidence and mortality rates
Melissa M Center
Intramural Research, American Cancer Society, Atlanta, GA 30303 1002, USA
Eur Urol 61:1079-92. 2012
..Wide variation exists internationally for prostate cancer (PCa) rates due to differences in detection practices, treatment, and lifestyle and genetic factors...
- Prostate-cancer mortality at 11 years of follow-up
Fritz H Schroder
Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
N Engl J Med 366:981-90. 2012
..We updated prostate-cancer mortality in the European Randomized Study of Screening for Prostate Cancer with 2 additional years of follow-up...
- The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
Department of Molecular Carcinogenesis, The University of Texas M D Anderson Cancer Center, Science Park, Smithville, Texas, USA
Nat Med 17:211-5. 2011
..Our study shows that miR-34a is a key negative regulator of CD44(+) prostate cancer cells and establishes a strong rationale for developing miR-34a as a novel therapeutic agent against prostate CSCs...
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono
Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK
Lancet 376:1147-54. 2010
..We aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment...
- Changes in circulating microRNA levels associated with prostate cancer
R J Bryant
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
Br J Cancer 106:768-74. 2012
..The aim of this study was to investigate the hypothesis that changes in circulating microRNAs (miRs) represent potentially useful biomarkers for the diagnosis, staging and prediction of outcome in prostate cancer...
- XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors
Department of Pathology and Cell Biology, Columbia University Medical Center, 622 West 168th Street, New York, NY 10032, USA
Proc Natl Acad Sci U S A 106:16351-6. 2009
..Our observations provide evidence for an association of XMRV with malignant cells and with more aggressive tumors...
- The development of androgen-independent prostate cancer
B J Feldman
Department of Medicine, Stanford University School of Medicine, California 94305 5103, USA
Nat Rev Cancer 1:34-45. 2001
- MicroRNA expression profiling in prostate cancer
Kati P Porkka
Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland
Cancer Res 67:6130-5. 2007
- Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma
Department of Biology, Free University, Berlin, Germany
Int J Cancer 126:1166-76. 2010
..Thus, differential miRNAs in prostate cancer are useful diagnostic and prognostic indicators. This study provides a solid basis for further functional analyses of miRNAs in prostate cancer...
- EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease
Department of Urology, RWTH University Aachen, Aachen, Germany
Eur Urol 59:61-71. 2011
..Our aim was to present a summary of the 2010 version of the European Association of Urology (EAU) guidelines on the screening, diagnosis, and treatment of clinically localised cancer of the prostate (PCa)...
- Disease-associated XMRV sequences are consistent with laboratory contamination
MRC Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland St, London W1T 4JF, UK
Retrovirology 7:111. 2010
..Controversy has arisen from the failure of some studies to detect XMRV in PC or CFS patients and from inconsistent detection of XMRV in healthy controls...
- Widespread deregulation of microRNA expression in human prostate cancer
Department of Pathology, Baylor College of Medicine, Houston, TX, USA
Oncogene 27:1788-93. 2008
..Our findings indicate that changes in miRNA expression may have an important role in the biology of human prostate cancer...
- Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines
Masonic Cancer Center, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Cancer Res 73:483-9. 2013
- An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression
Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Cancer Cell 17:443-54. 2010
..These findings provide a working model in which TMPRSS2-ERG plays a critical role in cancer progression by disrupting lineage-specific differentiation of the prostate and potentiating the EZH2-mediated dedifferentiation program...
- Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer
Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4258, USA
Cancer Res 68:6162-70. 2008
..In summary, microRNA expression becomes altered with the development and progression of prostate cancer. Some of these microRNAs regulate the expression of cancer-related genes in prostate cancer cells...
- The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
Jonathan I Epstein
Department of Pathology, Urology and Oncology, Johns Hopkins Hospital, Baltimore, MD 21231, USA
Am J Surg Pathol 29:1228-42. 2005
- Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer
Brett S Carver
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer Cell 19:575-86. 2011
- MicroRNA in prostate, bladder, and kidney cancer: a systematic review
James W F Catto
Institute for Cancer Studies and Academic Urology Unit, University of Sheffield, Sheffield, UK
Eur Urol 59:671-81. 2011
..Their altered expression and function have been observed in most urologic cancers. MiRNAs represent potential disease biomarkers and novel therapeutic targets...
- Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
A V D'Amico
Joint Center for Radiation Therapy, Harvard Medical School, Boston, Mass 02215, USA
JAMA 280:969-74. 1998
..Interstitial radiation (implant) therapy is used to treat clinically localized adenocarcinoma of the prostate, but how it compares with other treatments is not known...
- XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH
Rebecca S Arnold
Department of Urology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Urology 75:755-61. 2010
- Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Cell 138:245-56. 2009
..Thus, the role of AR in androgen-independent cancer cells is not to direct the androgen-dependent gene expression program without androgen, but rather to execute a distinct program resulting in androgen-independent growth...
- Recombinant origin of the retrovirus XMRV
Viral Mutation Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA
Science 333:97-101. 2011
- Quality of life and satisfaction with outcome among prostate-cancer survivors
Martin G Sanda
Departments of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Harvard University, Boston, MA 02215, USA
N Engl J Med 358:1250-61. 2008
- Metastasis to bone: causes, consequences and therapeutic opportunities
Gregory R Mundy
Department of Molecular Medicine, University of Texas Health Science Center, 7703 Floyd Curl Drive, MS 7877, San Antonio, Texas 78229 3900, USA
Nat Rev Cancer 2:584-93. 2002
- Molecular determinants of resistance to antiandrogen therapy
Charlie D Chen
Department of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA
Nat Med 10:33-9. 2004
..These findings provide insight toward the design of new antiandrogens...
- Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth
R Bruce Montgomery
Department of Medicine, University of Washington School of Medicine, Weattle, WA, USA
Cancer Res 68:4447-54. 2008
..Maximal therapeutic efficacy in the treatment of castration-resistant prostate cancer will require novel agents capable of inhibiting intracrine steroidogenic pathways within the prostate tumor microenvironment...
- Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Cancer Cell 8:393-406. 2005
- LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription
Universitäts Frauenklinik und Zentrum für Klinische Forschung, Klinikum der Universität Freiburg, Breisacherstrasse 66, 79106 Freiburg, Germany
Nature 437:436-9. 2005
..Here, we link demethylation of a repressive histone mark with androgen-receptor-dependent gene activation, thus providing a mechanism by which demethylases control specific gene expression...
- Mouse DNA contamination in human tissue tested for XMRV
Mark J Robinson
Section of Infectious Diseases, Jefferiss Research Trust Laboratories, Imperial College London, St Mary s Campus, London, W2 1PG, UK
Retrovirology 7:108. 2010
..To control for contamination, PCR assays to detect either mouse mitochondrial DNA (mtDNA) or intracisternal A particle (IAP) long terminal repeat DNA were run on all samples, owing to their very high copy number in mouse cells...
- Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy
Yan Ping Yu
University of Pittsburgh Cancer Institute and Department of Pathology, University of Pittsburgh, 3550 Terrace Street, Pittsburgh, PA 15261, USA
J Clin Oncol 22:2790-9. 2004
..Identification of the genes and patterns of gene expression will provide a more cohesive picture of prostate cancer biology...
- Androgen receptor in prostate cancer
Cynthia A Heinlein
George Whipple Laboratory for Cancer Research, Department of Pathology, University of Rochester, Rochester, NY 14642, USA
Endocr Rev 25:276-308. 2004
..The inhibition of AR activity through mechanisms in addition to androgen ablation, such as modulation of signal transduction pathways, may delay prostate cancer progression...
- Permutation tests for joinpoint regression with applications to cancer rates
H J Kim
Syracuse University, Department of Mathematics, 215 Carnegie Building, Syracuse University, Syracuse, NY 13244 1150, USA
Stat Med 19:335-51. 2000
..The performance of these tests are studied via simulations and the tests are applied to U.S. prostate cancer incidence and mortality rates...
- Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial
Sean M McBride
Harvard Radiation Oncology Program, Harvard University, 100 Blossom Street, 3, Boston, MA 02114, USA
Cancer 118:3681-90. 2012
..Here, the authors report on their own multi-institutional experience with extreme hypofractionated stereotactic radiotherapy for early stage disease...
- Development of a second-generation antiandrogen for treatment of advanced prostate cancer
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Science 324:787-90. 2009
..These compounds thus appear to be promising candidates for treatment of advanced prostate cancer...
- miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1
Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Via Montpellier, 1 00133 Rome, Italy
J Biol Chem 282:23716-24. 2007
- Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
Brett S Carver
Cancer Biology and Genetics Program, Sloan Kettering Institute, New York, New York, USA
Nat Genet 41:619-24. 2009
..Thus, ERG has a distinct role in prostate cancer progression and cooperates with PTEN haploinsufficiency to promote progression of HGPIN to invasive adenocarcinoma...
- Circulating miRNAs are correlated with tumor progression in prostate cancer
Jan C Brase
Division of Molecular Genome Analysis, German Cancer Research Center, Heidelberg, Germany
Int J Cancer 128:608-16. 2011
..Overall, our observations suggest that miRNA-375 and miRNA-141 expression is enhanced in prostate cancer specimens and their release into the blood is further associated with advanced cancer disease...
- Clinical features of metastatic bone disease and risk of skeletal morbidity
Robert E Coleman
Academic Unit of Medical Oncology, Weston Park Hospital, Sheffield, United Kingdom
Clin Cancer Res 12:6243s-6249s. 2006
..Our improved understanding of prognostic and predictive factors may enable delivery of a more personalized treatment for the individual patient and a more cost-effective use of health care resources...
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
Howard I Scher
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Lancet 375:1437-46. 2010
..Because growth of castration-resistant prostate cancer is dependent on continued androgen-receptor signalling, we assessed the antitumour activity and safety of MDV3100 in men with this disease...
- Transcriptome sequencing to detect gene fusions in cancer
Christopher A Maher
Michigan Center for Translational Pathology, Ann Arbor, USA
Nature 458:97-101. 2009
..Taken together, this study establishes a robust pipeline for the discovery of novel gene chimaeras using high-throughput sequencing, opening up an important class of cancer-related mutations for comprehensive characterization...
- XMRV: a new virus in prostate cancer?
Amanda L Aloia
HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702, USA
Cancer Res 70:10028-33. 2010
..It is possible that XMRV is not actually circulating in the human population; even if it is, the data do not seem to support a causal role for this virus in PCa...
- Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation
Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, MA 02215, USA
Sci Signal 3:ra29. 2010
..Thus, we have uncovered a proto-oncogenic miRNA-dependent network for PTEN regulation and defined the MCM7 locus as a critical factor in initiating prostate tumorigenesis...
- The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration
Department of Molecular Carcinogenesis, University of Texas M D Anderson Cancer Center, Science Park, Smithville, TX 78957, USA
Cell Stem Cell 10:556-69. 2012
..Altogether, our study suggests that PSA(-/lo) cells may represent a critical source of castration-resistant PCa cells...
- Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer
Institute of Biomedicine, Physiology, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
EMBO J 30:3962-76. 2011
..The role of FoxA1 in androgen signalling and prostate cancer is distinctly different from that in oestrogen signalling and breast cancer...
- MicroRNAs associated with metastatic prostate cancer
Department of Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
PLoS ONE 6:e24950. 2011
..The objective of this study was to identify down- and up-regulated miRNAs in prostate cancer that could provide potential biomarkers and/or therapeutic targets for prostate cancer metastasis...
- Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Scott M Lippman
Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
JAMA 301:39-51. 2009
..Secondary analyses of 2 randomized controlled trials and supportive epidemiologic and preclinical data indicated the potential of selenium and vitamin E for preventing prostate cancer...
- Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression
Embryology Laboratory, Murdoch Children s Research Institute, The Royal Children s Hospital, Victoria, Australia
J Cell Physiol 213:374-83. 2007
..Finally, perspectives from a clinical and translational viewpoint are discussed...
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Institut Gustave Roussy, University of Paris Sud, Villejuif, France
Lancet 377:813-22. 2011
..We compared denosumab, a human monoclonal antibody against RANKL, with zoledronic acid for prevention of skeletal-related events in men with bone metastases from castration-resistant prostate cancer...
- Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
Philip W Kantoff
Medical Director, BN ImmunoTherapeutics, 2425 Garcia Ave, Mountain View, CA 94043, USA
J Clin Oncol 28:1099-105. 2010
..PROSTVAC-VF treatment was evaluated for safety and for prolongation of progression-free survival (PFS) and overall survival (OS) in a randomized, controlled, and blinded phase II study...
- Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells
Emily C Knouf
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
J Virol 83:7353-6. 2009
- Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer
Johann S de Bono
Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, United Kingdom
Clin Cancer Res 14:6302-9. 2008
..Secondary objectives included determining the prognostic utility of CTC measurement before initiating therapy, and the relationship of CTC to prostate-specific antigen (PSA) changes and OS at these and other time points...
- Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143 1708, and Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
Int J Radiat Oncol Biol Phys 65:965-74. 2006
..For example, if the median follow-up is 5 years, control rates at 3 years should be cited. Retaining a strict version of the ASTRO definition would allow comparisons with a large existing body of literature...
- Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells
Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, USA
Mol Cell Biol 31:4648-62. 2011
..This allows the recruitment of histone modifiers, chromatin remodelers, and ultimately gene activation. The "receptive" state described here could help explain AR signaling activation under very low ligand concentrations...
- Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone
Russell S Taichman
Department of Periodontics, Prevention, and Geriatrics, and the Center for Biorestoration of Oral Health, School of Dentistry, University of Michigan, Ann Arbor, Michigan 48109 1078, USA
Cancer Res 62:1832-7. 2002
..Collectively, these results suggest that prostate cancers and perhaps other neoplasms may use the SDF-1/CXCR4 pathway to spread to bone...
- Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers
Department of Genome Sciences, University of Washington, Seattle, WA 98105, USA
Proc Natl Acad Sci U S A 108:17087-92. 2011
..Our results also suggest that increasingly deep catalogs of human germline variation may challenge the necessity of sequencing matched tumor-normal pairs...
- Nucleosome dynamics define transcriptional enhancers
Housheng Hansen He
Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard School of Public Health, Boston, Massachusetts, USA
Nat Genet 42:343-7. 2010
..Therefore, quantitative modeling of enhancer structure provides a powerful predictive method to infer the identity of transcription factors involved in cellular responses to specific stimuli...
- Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force
Oregon Health and Science University, Portland, Oregon 97239, USA
Ann Intern Med 155:762-71. 2011
..Screening can detect prostate cancer at earlier, asymptomatic stages, when treatments might be more effective...
- Mechanisms of bone metastasis
G David Roodman
Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, School of Medicine Hematology, The University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
N Engl J Med 350:1655-64. 2004
- Isolation of circulating tumor cells using a microvortex-generating herringbone-chip
Shannon L Stott
Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Proc Natl Acad Sci U S A 107:18392-7. 2010
..In a subset of patient samples, the low shear design of the HB-Chip revealed microclusters of CTCs, previously unappreciated tumor cell aggregates that may contribute to the hematogenous dissemination of cancer...
- Molecular genetics of prostate cancer: new prospects for old challenges
Michael M Shen
Department of Medicine, Columbia University Medical Center, New York, New York 10032, USA
Genes Dev 24:1967-2000. 2010
..Overall, we highlight the tremendous research progress made in recent years, and underscore the challenges that lie ahead...
- The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
Charles E Massie
CRUK Cambridge Research Institute, Cambridge, UK
EMBO J 30:2719-33. 2011
..In conclusion, it is possible to progress from transcriptional studies to a promising therapeutic target by taking an unbiased interdisciplinary approach...
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
Matthew R Smith
Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
Lancet 379:39-46. 2012
..We assessed denosumab, a fully human anti-RANKL monoclonal antibody, for prevention of bone metastasis or death in non-metastatic castration-resistant prostate cancer...
- Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study
The Institute of Cancer Research, Sutton, Surrey, UK
Nat Genet 43:785-91. 2011
..7 × 10(-24)). We also identified a SNP in TERT more strongly associated with PrCa than that previously reported. More than 40 PrCa susceptibility loci, explaining ∼25% of the familial risk in this disease, have now been identified...
- An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Proc Natl Acad Sci U S A 104:1655-60. 2007
..Our studies demonstrate that XMRV is a virus that has infected humans and is susceptible to inhibition by IFN and its downstream effector, RNase L...
- Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation
Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
Nat Genet 40:741-50. 2008
..These data establish EZH2-mediated H3K27triM as a mechanism of tumor-suppressor gene silencing in cancer that is potentially independent of promoter DNA methylation...
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
Philip A Watson
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Proc Natl Acad Sci U S A 107:16759-65. 2010
- Identification of a cell of origin for human prostate cancer
Andrew S Goldstein
Molecular Biology Institute, University of California, Los Angeles UCLA, Los Angeles, CA 90095, USA
Science 329:568-71. 2010
..Our results demonstrate that histological characterization of cancers does not necessarily correlate with the cellular origins of the disease...
- A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer
The Gade Institute, Section for Pathology, University of Bergen, Haukeland University Hospital, Bergen, Norway
Clin Cancer Res 13:7003-11. 2007
..We here present novel data, with special focus on the independent relationship between an E-cadherin to N-cadherin switch (EN-switch) and patient prognosis...
- Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Scott A Tomlins
Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Nature 448:595-9. 2007
..Furthermore, the identification of androgen-repressed and insensitive 5' fusion partners may have implications for the anti-androgen treatment of advanced prostate cancer...
- Prostate cancer incidence and mortality trends in 37 European countries: an overview
Cancer Information Section, International Agency for Research on Cancer, Lyon, France
Eur J Cancer 46:3040-52. 2010
..The increase in mortality observed in the Baltic region and in several Central and Eastern European countries appear to reflect a real increase in risk and requires further monitoring...
- Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
Ian M Thompson
Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Tex, USA
N Engl J Med 350:2239-46. 2004
..We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 4.0 ng per milliliter or less...
- Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells
Department of Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park Research Division, Smithville, 78957, USA
Oncogene 25:1696-708. 2006
..Altogether, our results suggest that the CD44(+) PCa cell population is enriched in tumorigenic and metastatic progenitor cells...
- Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer
Jennifer A Locke
Department of Urologic Sciences, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada
Cancer Res 68:6407-15. 2008
..This evidence suggests that de novo androgen synthesis may be a driving mechanism leading to CRPC progression following castration...
- Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer
Zumre A Alicikus
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Cancer 117:1429-37. 2011
..The authors investigated long-term tumor control and toxicity outcomes after high-dose, intensity-modulated radiation therapy (IMRT) in patients who had clinically localized prostate cancer...
- miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth
The James Buchanan Brady Urological Institute, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Cancer Res 69:7165-9. 2009
..Moreover, quantitative reverse transcription-PCR analysis revealed elevated miR-21 expression in CaP when compared with adjacent normal tissue. These results suggest that miR-21 may contribute to CaP pathogenesis...
- Effect of dutasteride on the risk of prostate cancer
Gerald L Andriole
Division of Urology, Washington University School of Medicine in St Louis, St Louis, MO 63110, USA
N Engl J Med 362:1192-202. 2010
..We conducted a study to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease...
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98104, USA
J Clin Invest 120:2715-30. 2010
- Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor
Raymond J Andersen
Chemistry and Earth and Ocean Sciences, University of British Columbia, 2036 Main Mall, Vancouver, BC, Canada V6T 1Z1
Cancer Cell 17:535-46. 2010
..Importantly, EPI-001 blocked androgen-induced proliferation and caused cytoreduction of CRPC in xenografts dependent on AR for growth and survival without causing toxicity...
- Radiation-induced second cancers: the impact of 3D-CRT and IMRT
Eric J Hall
Center for Radiological Research, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
Int J Radiat Oncol Biol Phys 56:83-8. 2003
..75% for patients surviving 10 years. The numbers may be larger for longer survival (or for younger patients), but the ratio should remain the same...
- Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer
Howard Hughes Medical Institute, University of California Los Angeles School of Medicine, 90095, Los Angeles, CA, USA
Cancer Cell 4:209-21. 2003
..This murine prostate cancer model provides a unique tool for both exploring the molecular mechanism underlying prostate cancer and for development of new targeted therapies...
- Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells
Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, United States of America
PLoS ONE 5:e12445. 2010
..Increasing evidence suggests that EMT-type cells share many biological characteristics with cancer stem-like cells...
- Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer
R E Reiter
Department of Urology, University of California, Los Angeles, CA 90095, USA
Proc Natl Acad Sci U S A 95:1735-40. 1998
..A mouse homologue with 70% amino acid identity and similar genomic organization to human PSCA has also been identified. These results support PSCA as a target for prostate cancer diagnosis and therapy...
- Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer
Department of Urology, Oncology, and Pathology, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
Cancer Res 69:16-22. 2009
..In addition, as expression markers for lethal PCa, these novel AR variants may be explored as potential biomarkers and therapeutic targets for advanced PCa...
- Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer
E S Martens-Uzunova
Department of Urology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands
Oncogene 31:978-91. 2012
..Our findings provide miRNA expression signatures that may serve as an accurate tool for the diagnosis and prognosis of PCa...